In the case of Virax (VHL), administrators from Grant Thorton created a DOCA that included establishment of a "Creditors Trust".
Under this arrangement, the recapitalized cancer drug company is required
to pay some $7.7m to creditors from funds that may flow from milestone payments, royalties and other income.
